Y Intercept Hong Kong Ltd Purchases 28,586 Shares of Haemonetics Corporation $HAE

Posted by on Jul 8th, 2026

Y Intercept Hong Kong Ltd raised its holdings in shares of Haemonetics Corporation (NYSE:HAE – Free Report) by 125.7% in the first quarter, Holdings Channel reports. The institutional investor owned 51,334 shares of the medical instruments supplier’s stock after buying an additional 28,586 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Haemonetics were worth $2,893,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Invenomic Capital Management LP raised its holdings in Haemonetics by 1,691.5% in the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock valued at $24,288,000 after acquiring an additional 470,502 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC grew its holdings in shares of Haemonetics by 16.5% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 559,972 shares of the medical instruments supplier’s stock worth $27,293,000 after purchasing an additional 79,138 shares during the last quarter. Aristotle Capital Boston LLC grew its stake in Haemonetics by 11.4% during the third quarter. Aristotle Capital Boston LLC now owns 404,162 shares of the medical instruments supplier’s stock worth $19,699,000 after buying an additional 41,215 shares during the last quarter. North Peak Capital Management LLC increased its holdings in shares of Haemonetics by 204.4% during the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after buying an additional 740,626 shares in the last quarter. Finally, Strs Ohio acquired a new stake in shares of Haemonetics during the fourth quarter worth approximately $986,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Up 0.0%

Haemonetics stock opened at $75.04 on Wednesday. The firm has a market capitalization of $3.41 billion, a price-to-earnings ratio of 37.15, a PEG ratio of 1.51 and a beta of 0.52. The company’s 50 day simple moving average is $67.43 and its 200 day simple moving average is $66.37. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $87.32.

Haemonetics (NYSE:HAE – Get Free Report) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.01. The company had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the business posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, sell-side analysts anticipate that Haemonetics Corporation will post 5.22 EPS for the current year.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of research analyst reports. Robert W. Baird set a $67.00 price target on Haemonetics in a research report on Friday, May 8th. Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. lowered their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Mizuho upped their target price on shares of Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. Finally, Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and increased their price target for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $78.33.

Get Our Latest Research Report on Haemonetics

Haemonetics Company Profile

(Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Read More

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE – Free Report).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.